Primary cutaneous plasmacytoma occurring after pacemaker implantation and recurring in scar tissue

Li, Anthony; Chen, Alexander; Gallagher, Mark; Kaczmarek, Pawel; Tinwell, Brendan; Sneddon, James; Cliff, S.

doi:10.5070/d36cf6s5t4

Cited by 10 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we show an indirect effect on 5TGM1 MM PC proliferation when cultured with CM from MPO‐treated OP9 cells, which may be attributable to the upregulation of IL6. Interestingly, several case studies have detailed plasmacytoma occurrence at sites of local trauma and inflammation in MGUS patients, 47 , 48 , 49 supporting the hypothesis that inflammation represents a key driving factor in the homing and/or outgrowth of malignant PCs. Collectively, these studies suggest that local trauma and the associated induction of pro‐inflammatory pathways, which we postulate include increased MPO activity, aid in establishing a favourable niche for MM development.…”

Section: Discussionmentioning

confidence: 90%

Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma

Williams,

Noll,

Bradey

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryExpression of myeloperoxidase (MPO), a key inflammatory enzyme restricted to myeloid cells, is negatively associated with the development of solid tumours. Activated myeloid cell populations are increased in multiple myeloma (MM); however, the functional consequences of myeloid‐derived MPO within the myeloma microenvironment are unknown. Here, the role of MPO in MM pathogenesis was investigated, and the capacity for pharmacological inhibition of MPO to impede MM progression was evaluated. In the 5TGM1‐KaLwRij mouse model of myeloma, the early stages of tumour development were associated with an increase in CD11b+ myeloid cell populations and an increase in Mpo expression within the bone marrow (BM). Interestingly, MM tumour cell homing was increased towards sites of elevated myeloid cell numbers and MPO activity within the BM. Mechanistically, MPO induced the expression of key MM growth factors, resulting in tumour cell proliferation and suppressed cytotoxic T‐cell activity. Notably, tumour growth studies in mice treated with a small‐molecule irreversible inhibitor of MPO (4‐ABAH) demonstrated a significant reduction in overall MM tumour burden. Taken together, our data demonstrate that MPO contributes to MM tumour growth, and that MPO‐specific inhibitors may provide a new therapeutic strategy to limit MM disease progression.

show abstract

Section: Discussionmentioning

confidence: 90%

Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma

Williams,

Noll,

Bradey

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Moreover, one cutaneous localization after pacemaker implantation 4 and two secondary localizations occurring on the tract of central venous catheters 5 have been reported. They were mainly nodular forms, such as our patients.…”

Section: Figurementioning

confidence: 99%

Cutaneous secondary localization of multiple myeloma at Heparin injection sites

Borg

Guenot

Tichadou³

et al. 2023

Skin Health and Disease

View full text Add to dashboard Cite

show abstract

“…The IgG level was 53.2 g/L (normal range 5.0–15.0 g/L) and B2-microglobulin level was 5.59 mg/L (normal range 0–1.9 mg/L). Cutaneous plasmacytomas have been known to develop at sites of previous surgery or trauma, whether as a secondary lesion in patients with known plasma cell disorders [ 4 , 5 ] or as a primary lesion [ 6 , 7 ]. However, we believe that this is the first description of a primary plasma cell disorder presenting with both osseous and extramedullary disease at the site of previous sternotomy.…”

mentioning

confidence: 99%

“…The predilection of plasma cell neoplasms for sites of injury or scar formation is not well understood. It has been postulated that the inflammatory mediators present in scar tissue to facilitate wound healing (such as interleukin-6, interleukin-8, and tumour growth factor-β) can result in the selection of a clonal plasma cell population and also support tumour growth and survival [5,7]. [11].…”

mentioning

confidence: 99%

Multiple Myeloma: Case of a “Moving” Sternal Wire

et al. 2023

View full text Add to dashboard Cite

Multiple myeloma generally occurs in older adults, with the clonal proliferation of plasma cells and accumulation of monoclonal protein resulting in a broad range of clinical manifestations and complications, including hypercalcemia, renal dysfunction, anaemia, and bone destruction (termed CRAB features). A 64-year-old man with no history of malignancy presented with an enlarging precordial lump occurring three years post-sternotomy for uneventful coronary artery bypass grafting surgery. Initial investigations showed anaemia and impaired renal function. Multimodal imaging performed for further evaluation showcases the radio-pathological features which can be encountered in haematological malignancy. Subsequent percutaneous biopsy confirmed an underlying plasma cell neoplasm, and a diagnosis of multiple myeloma was achieved. The prompt resolution of the lesions upon the initiation of treatment highlights the importance of early diagnosis and treatment.

show abstract

Primary cutaneous plasmacytoma occurring after pacemaker implantation and recurring in scar tissue

Cited by 10 publications

References 0 publications

Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma

Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma

Cutaneous secondary localization of multiple myeloma at Heparin injection sites

Multiple Myeloma: Case of a “Moving” Sternal Wire

Contact Info

Product

Resources

About